Clinical trials set for breakthrough sickle cell gene therapy technique
Using the patients’ own bone marrow
Lisa Olivia Fitch | 8/1/2013, midnight
When you think sickle cell disease, you think of a crippling, painful, life-shortening disease that affects some in the Black community. And when you think stem cell research, you think of the controversy and the drama that surrounded President Barack Obama when he repealed a Bush-era policy limiting federal tax dollars for embryonic stem cell research. Obama signed that executive order in 2009.
Well, the two worlds have met, but it’s really not as controversial as it might seem.
“Not all stem cell research involves the creation, use, or destruction of human embryos,” Donald Kohn, M.D., a professor of pediatrics and microbiology, immunology and molecular genetics in the life sciences said. “Bone marrow has a specific type of stem cell,” Kohn said. “Not like the embryonic ones that all the controversy is about. These are adult stems cells.”
Kohn led researchers at UCLA’s Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research in successfully establishing a method of using hematopoietic (blood-producing) stem cells from the bone marrow of patients with sickle cell disease to treat their own disease.
The breakthrough gene therapy technique for sickle cell disease is scheduled to begin clinical trials by early 2014.
Prior approaches to treating sickle cell disease involved finding a matched bone marrow donor. Because the markers used in matching are inherited, patients are more likely to match someone from their own ancestry.
Thousands of patients with sickle cell, blood cancers and other life-threatening diseases depend on the Be The Match Registry to find a match to save their life. This program has been operated by the National Marrow Donor Program for more than 25 years and has been helping patients receive life-saving transplants.
The Be The Match Registry encourages African Americans to join at http://bethematch.org/join, because there aren’t enough donors for Blacks. Doctors request donors in the 18-44 age group 90 percent of the time to help patients with sickle cell; blood cancers like leukemia and lymphoma; and other life-threatening diseases.
The new UCLA therapy involves extracting the patient’s own hematopoietic (blood-producing) stem cells from their bone marrow, then introducing an anti-sickling gene into those cells to capitalize on the self-renewing potential of stem cells and create a continual source of healthy red blood cells that do not sickle.
This approach does not rely on finding a donor, or risking rejection of donor cells.
“Clinical trials are needed,” Kohn said. “We are engineering cells and putting in a new copy of a beta globin gene—part of hemoglobin, which is the main protein in red blood cells that carry oxygen around.”
“People with sickle cell have inherited a version of the beta globin gene that has a mistake in it,” Kohn explained. “That abnormal hemoglobin makes red cells become stiff and sickle-shaped when their oxygen is low.”
The brittle, sickle-shaped cells have a harder time flowing through the patient’s narrow capillaries. Repeated episodes of sickling damage the cell membrane and decrease the cell’s elasticity. Healthy red blood cells typically live 90-120 days, but sickle cells only survive 10-20 days.